HLA-DRB1和HLA-DQ基因多态性与红细胞同种免疫的关联性

doi:10.3969/j.issn.1671-2587.2025.04.020

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (4): 563-571.DOI: 10.3969/j.issn.1671-2587.2025.04.020

HLA-DRB1和HLA-DQ基因多态性与红细胞同种免疫的关联性

宋文倩¹, 余婉珍², 梁晓华¹, 周世航¹

¹大连市血液中心血型研究室,大连辽宁 116001;
²大连医科大学检验医学院,大连辽宁 116001

收稿日期:2025-01-09 发布日期:2025-08-22
通讯作者: 梁晓华,主要从事血型免疫方面研究,（E-mail）liangxiaohua1968@126.com。共同通信作者：周世航,主要从事血型免疫方面研究,（E-mail）zshsail@163.com。
作者简介:宋文倩,主要从事血型免疫方面研究,（E-mail）wenqian_song@163.com。并列第一作者：余婉珍,主要从事血型免疫方面研究,（E-mail）2519315783@qq.com。

Association between HLA-DRB1 and HLA-DQ Gene Polymorphisms and Red Blood Cell Alloimmunization

SONG Wenqian¹, YU Wanzhen², LIANG Xiaohua¹, ZHOU Shihang¹

¹Blood Group Laboratory, Dalian Blood Center, Dalian 116001;
²Dalian Medical University, School of Laboratory Medicine, Dalian 116001

Received:2025-01-09 Published:2025-08-22

摘要/Abstract

摘要： 红细胞同种免疫是临床输血重要的免疫学问题,其本质为机体识别外源红细胞抗原并产生特异性抗体,严重时可导致溶血性输血反应或新生儿溶血症。该免疫反应可能依赖于HLA-Ⅱ类分子介导的抗原呈递机制,涉及树突状细胞处理抗原、CD4⁺ T细胞识别并激活、辅助B细胞产生IgG类抗体等环节。个体在暴露同种抗原后是否产生抗体与其接受剂量、免疫状态、炎症环境及遗传背景密切相关。HLA-Ⅱ基因的高度多态性决定了个体对特定红细胞抗原的应答差异,部分等位基因如HLA-DRB1^*04与HLA-DRB1^*15可增强肽段呈递能力,显著提高抗体生成风险,而某些HLA-Ⅱ类等位基因则表现出保护作用。本文系统梳理以HLA-DRB1和HLA-DQ为代表的HLA-Ⅱ类基因与红细胞同种免疫抗体生成的关联及可能机制,旨在为临床个体化输血策略和免疫预测提供理论依据。

关键词: 红细胞, 同种免疫抗体, HLA, 基因多态性

Abstract: Red blood cell (RBC) alloimmunization is a significant immunological concern in clinical transfusion. It refers to the immune response wherein the recipient recognizes foreign RBC antigens and produces specific antibodies, potentially leading to hemolytic transfusion reactions or hemolytic disease of the fetus and newborn in severe cases. This immune process is possible dependent on the antigen presentation mechanism mediated by HLA class Ⅱ molecules, involving the presentation of antigens by dendritic cells, recognition and activation by CD4⁺ T cells, and subsequent help to produce IgG antibody by B cells. Whether an individual develops antibodies upon exposure to alloantigens is closely related to dosage,their immune status, inflammatory environment, and genetic background. The high polymorphism of HLA class Ⅱ genes underlies the inter-individual variability in immune responses to specific RBC antigens. Certain alleles, such as HLA-DRB1^*04 and DRB1^*15, have been shown to enhance peptide presentation capabilities, significantly increasing the risk of antibody formation. In contrast, some HLA class Ⅱ alleles may exhibit protective effects. Here we systematically reviewed the association and potential mechanisms between HLA class Ⅱ genes, represented by HLA-DRB1 and HLA-DQ, and the development of RBC alloantibodies. The aim is to provide a theoretical basis for individualized transfusion strategies and immune risk prediction in clinical practice.

Key words: Red blood cells, Alloimmune antibodies, HLA, Gene polymorphism

中图分类号:

R457.1

宋文倩, 余婉珍, 梁晓华, 周世航. HLA-DRB1和HLA-DQ基因多态性与红细胞同种免疫的关联性[J]. 临床输血与检验, 2025, 27(4): 563-571.

SONG Wenqian, YU Wanzhen, LIANG Xiaohua, ZHOU Shihang. Association between HLA-DRB1 and HLA-DQ Gene Polymorphisms and Red Blood Cell Alloimmunization[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(4): 563-571.

参考文献

[1] DAVENPORT R D.Pathophysiology of hemolytic transfusion reactions[J]. Semin Hematol,2005,42(3): 165-168.
[2] NORDVALL M,DZIEGIEL M,HEGAARD H K,et al.Red blood cell antibodies in pregnancy and their clinical consequences:synergistic effects of multiple specificities[J]. Transfusion,2009,49(10):2070-2075.
[3] EDER A F.Update on HDFN:new information on long-standing controversies[J]. Immunohematology, 2006,22(4):188-195.
[4] TORMEY C A,HENDRICKSON J E.Transfusion-related red blood cell alloantibodies:induction and consequences[J]. Blood,2019,133(17):1821-1830.
[5] HOELTGE G A,DOMEN R E,RYBICKI L A,et al.Multiple red cell transfusions and alloimmunization. Experience with 6 996 antibodies detected in a total of 159 262 patients from 1985 to 1993[J]. Arch Pathol Lab Med,1995,119(1):42-45.
[6] WINTERS J L,PINEDA A A,GORDEN L D,et al.RBC alloantibody specificity and antigen potency in Olmsted County,Minnesota[J]. Transfusion,2001,41(11):1413-1420.
[7] WALKER R H,LIN D T,HARTRICK M B.Alloimmunization following blood transfusion[J]. Arch Pathol Lab Med,1989,113(3):254-261.
[8] SPIELMANN W,SEIDL S.Prevalence of irregular red cell antibodies and their significance in blood transfusion and antenatal care[J]. Vox Sang,1974,26(6): 551-559.
[9] HEDDLE N M,SOUTAR R L,O'HOSKI P L,et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion[J]. Br J Haematol,1995,91(4):1000-1005.
[10] REDMAN M,REGAN F,CONTRERAS M.A prospective study of the incidence of red cell allo-immunisation following transfusion[J]. Vox Sang,1996,71(4):216-220.
[11] FLUIT C R,KUNST V A,DRENTHE-SCHONK A M. Incidence of red cell antibodies after multiple blood transfusion[J]. Transfusion,1990,30(6):532-535.
[12] AMEEN R,AL-SHEMMARI S,AL-HUMOOD S,et al.RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients[J].Transfusion,2003,43(11):1604-1610.
[13] SCHONEWILLE H,HAAK H L,VAN ZIJL A M. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases[J]. Transfusion,1999,39(7):763-771.
[14] PERSEGHIN P,BALDUZZI A,GALIMBERTI S,et al.Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation[J]. Bone Marrow Transplant,2003,32(2):231-236.
[15] ROSSE W F,GALLAGHER D,KINNEY T R,et al.Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease[J]. Blood, 1990,76(7):1431-1437.
[16] STACK G,TORMEY C A.Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence[J]. Transfusion,2016,56(11):2662-2667.
[17] HENDRICKSON J E.Red blood cell alloimmunization and sickle cell disease:a narrative review on antibody induction[J]. Ann Blood,2020,5:33.
[18] YAZER M H,TRIULZI D J,SHAZ B,et al.Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization?[J]. Transfusion,2009, 49(6):1070-1075.
[19] SCHONEWILLE H,BRAND A.Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens?[J]. Transfusion, 2008,48(5):958-963.
[20] YAZDANBAKHSH K,WARE R E,NOIZAT-PIRENNE F.Red blood cell alloimmunization in sickle cell disease:pathophysiology,risk factors,and transfusion management[J]. Blood,2012,120(3):528-537.
[21] HENDRICKSON J E,HOD E A,SPITALNIK S L, et al.IMMUNOHEMATOLOGY:Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen[J]. Transfusion, 2010,50(3):642-648.
[22] HENDRICKSON J,DESMARETS M,DESHPANDE S, et al.Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells[J]. Transfusion,2006,46(9):1526-1536.
[23] CHOO S Y.The HLA system:genetics,immunology, clinical testing,and clinical implications[J]. Yonsei Med J, 2007,48(1):11-23.
[24] WONG K,LAI W K,JACKSON D E.HLA Class Ⅱ regulation of immune response in sickle cell disease patients:Susceptibility to red blood cell alloimmunization (systematic review and meta-analysis)[J]. Vox Sang,2022,117(11):1251-1261.
[25] HICKEY M J,VALENZUELA N M,REED E F.Alloantibody generation and effector function following sensitization to human leukocyte antigen[J]. Front Immunol,2016,7:30.
[26] 安万新. 输血技术学[M]. 北京: 科学技术文献出版社, 2006:91.
[27] SYEDA M Z,HONG T,HUANG C M,et al.B cell memory:from generation to reactivation:a multipronged defense wall against pathogens[J]. Cell Death Discov, 2024,10(1):117.
[28] RODRIGUES C,SELL A M,GUELSIN G S,et al.HLA polymorphisms and risk of red blood cell alloimmunisation in polytransfused patients with sickle cell anaemia[J]. Transfus Med,2017,27(6):437-443.
[29] MCPHERSON M E,ANDERSON A R,CASTILLEJO M I, et al.HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease[J]. Pediatr Blood Cancer,2010,54(4):552-558.
[30] TELEN M J,AFENYI-ANNAN A,GARRETT M E, et al.Alloimmunization in sickle cell disease:changing antibody specificities and association with chronic pain and decreased survival[J]. Transfusion,2015,55(6 Pt 2): 1378-1387.
[31] STOTT L M,BARKER R N,URBANIAK S J.Identification of alloreactive T-cell epitopes on the Rhesus D protein[J]. Blood,2000,96(13):4011-4019.
[32] STEPHEN J,CAIRNS L S,PICKFORD W J,et al.Identification, immunomodulatory activity, and immunogenicity of the major helper T-cell epitope on the K blood group antigen[J]. Blood,2012,119(23):5563-5574.
[33] MILOSAVIĆ M,LILIĆ M,ANDRIĆ Z.Impact of human leucocyte antigen class II polymorphism on anti-red blood cell antibody development:Correlations and indications[J]. Vox Sang,2024,119(7):720-727.
[34] GODEFROY E,ZHONG H,PHAM P,et al.TIGIT-positive circulating follicular helper T cells display robust B-cell help functions:potential role in sickle cell alloimmunization[J]. Haematologica, 2015,100(11): 1415-1425.
[35] VINGERT B,TAMAGNE M,HABIBI A,et al.Phenotypic differences of CD4+ T cells in response to red blood cell immunization in transfused sickle cell disease patients[J]. Eur J Immunol,2015,45(6):1868-1879.
[36] BALBUENA-MERLE R,SANTHANAKRISHNAN M,DEVINE L,et al.Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status[J]. Transfus Apher Sci,2020,59(4):102778.
[37] GERRITSMA J J,OOMEN I,MEINDERTS S,et al.Back to base pairs:What is the genetic risk for red bloodcell alloimmunization?[J]. Blood Rev,2021,48:100794.
[38] MEINDERTS S M,GERRITSMA J J,SINS J W R,et al. Identification of genetic biomarkers for alloimmunization in sickle cell disease[J]. Br J Haematol,2019,186(6):887-899.
[39] NOIZAT-PIRENNE F,TOURNAMILLE C,BIERLING P, et al.Relative immunogenicity of Fya and K antigens in a Caucasian population,based on HLA classⅡ restriction analysis[J]. Transfusion,2006,46(8):1328-1333.
[40] SIPPERT E Â,VISENTAINER J E L,ALVES H V,et al. Red blood cell alloimmunization in patients with sickle cell disease:correlation with HLA and cytokine gene polymorphisms[J]. Transfusion,2017,57(2):379-389.
[41] NATARAJAN P,LIU D,PATEL S R,et al.CD4 depletion or CD40L blockade results in antigen-specific tolerance in a red blood cell alloimmunization model[J]. Front Immunol,2017,8:907.
[42] ARTHUR C M,PATEL S R,SMITH N H,et al.Antigen density dictates immune responsiveness following red blood cell transfusion[J]. J Immunol, 2017,198(7):2671-2680.
[43] ZHONG H,BAO W L,FRIEDMAN D,et al.Hemin controls T cell polarization in sickle cell alloimmunization[J]. J Immunol,2014,193(1):102-110.
[44] MATTEOCCI A,PIERELLI L.Red blood cell alloimmunization in sickle cell disease and in thalassaemia:current status,future perspectives and potential role of molecular typing[J]. Vox Sang,2014, 106(3):197-208.
[45] LOUIS K,MACEDO C,METES D.Targeting T follicular helper cells to control humoral allogeneic immunity[J]. Transplantation,2021,105(11):e168-e180.
[46] NICKEL R S,HORAN J T,FASANO R M,et al.Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion[J]. Am J Hematol,2015, 90(12): 1135-1141.
[47] BALANDYA E,REYNOLDS T,OBARO S,et al.Alteration of lymphocyte phenotype and function in sickle cell Anemia:Implications for vaccine responses[J]. Am J Hematol,2016,91(9):938-946.
[48] BLANCO P,KAROLINA PALUCKA A,PASCUAL V,et al.Dendritic cells and cytokines in human inflammatory and autoimmune diseases[J]. Cytokine Growth Factor Rev,2008,19(1):41-52.
[49] FASANO R M,BOOTH G S,MILES M,et al.Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease[J]. Br J Haematol,2015,168(2): 291-300.
[50] EVERS D,VAN DER BOM J G,TIJMENSEN J,et al. Red cell alloimmunisation in patients with different types of infections[J]. Br J Haematol,2016,175(5):956-966.
[51] RYDER A B,HENDRICKSON J E,TORMEY C A.Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization[J]. Br J Haematol,2016,174(3):483-485.
[52] KARAFIN M S,WESTLAKE M,HAUSER R G, et al.Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-Ⅲ) database[J]. Br J Haematol,2018,181(5): 672-681.
[53] WALKER L S K. The link between circulating follicular helper T cells and autoimmunity[J]. Nat Rev Immunol,2022,22(9):567-575.
[54] ZHOU R,LUO Y B,ZENG Q M,et al.Regulatory B cells and its role in central nervous system inflammatory demyelinating diseases[J]. Front Immunol,2020,11:1884.
[55] JAIN A,SHARMA R R,MINZ R W,et al.Association of HLA-DRB1 alleles with anti-D alloimmunization in RhD negative pregnant women in India[J]. Transfus Apher Sci,2023,62(6):103789.
[56] KONG Y J,XIAO J,TIAN L,et al.The influence of HLA allele and haplotype on RhE alloimmunization among pregnant females in the Chinese Han population[J]. Vox Sang,2024,119(7):737-744.
[57] SCHONEWILLE H,DOXIADIS I I N,LEVERING W H B M,et al. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies[J]. Transfusion,2014,54(8):1971-1980.
[58] GUNASEKERA D,ZIMRING J C,PRATT K P.A unique major histocompatibility complex Class Ⅱ-binding register correlates with HLA-DR11-associated immunogenicity of the major K blood group antigen[J]. Transfusion,2018,58(5):1171-1181.
[59] DE SOUZA C P,BALEOTTI W,MORITZ E,et al. HLA-DRB1 molecules and the presentation of anchor peptides from RhD,RhCE,and KEL proteins[J]. Transfusion, 2021,61(5):1617-1630.
[60] MALUSKOVA A,MRAZEK F,PAULISKOVA M, et al.Association of HLA-DRB1 and HLA-DQB1 with red-blood-cell alloimmunization in the Czech population[J]. Vox Sang,2017,112(2):156-162.
[61] PICARD C,FRASSATI C,BASIRE A,et al.Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population[J]. Transfusion, 2009,49(11):2412-2417.
[62] RAOS M,ZUNEC R,MOCIBOB M,et al.Susceptible and protective HLA-DR and HLA-DQ alleles for Fy^a alloimmunization in the Croatian population[J]. Transfusion, 2019,59(3):1118-1124.
[63] REVIRON D,DETTORI I,FERRERA V,et al.HLA-DRB1 alleles and Jka immunization[J]. Transfusion, 2005,45(6):956-959.
[64] BALEOTTI W Jr,RUIZ M O,FABRON A Jr,et al.HLA-DRB1*07:01 allele is primarily associated with the Diego a alloimmunization in a Brazilian population[J]. Transfusion,2014,54(10):2468-2476.
[65] MALUSKOVA A,MRAZEK F,KOZELSKA R, et al.Association of multispecific red blood cell alloimmunization with HLA-Class Ⅱ variants is related to Rh phenotypes[J]. Bratisl Lek Listy,2021,122(3): 179-183.
[66] VERDUIN E P,BRAND A,VAN DE WATERING L M G, et al. The HLA-DRB1*15 phenotype is associated with multiple red blood cell and HLA antibody responsiveness[J]. Transfusion,2016,56(7):1849-1856.

HLA-DRB1和HLA-DQ基因多态性与红细胞同种免疫的关联性

Association between HLA-DRB1 and HLA-DQ Gene Polymorphisms and Red Blood Cell Alloimmunization

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	梁延连, 梁耀鹏, 唐雄驰. 孕期母亲血浆抗-M抗体对M抗原阳性红细胞凋亡速率的影响^*[J]. 临床输血与检验, 2025, 27(4): 451-456.
[2]	安立, 刘群, 王秀芝, 刘艳, 贡觉顿珠, 赵爱平, 梁雪峰, 庄云龙. X射线辐照对淋巴细胞凋亡及红细胞血液质量影响的研究^*[J]. 临床输血与检验, 2025, 27(4): 484-491.
[3]	张咏, 耿良权, 强萍, 范倩, 刘会兰. ABO血型主要及双向不合对757例非血缘脐血移植结局的影响分析^*[J]. 临床输血与检验, 2025, 27(4): 518-525.
[4]	赵桐茂. RhCE抗原错配是中国输血患者的主要风险[J]. 临床输血与检验, 2025, 27(3): 289-290.
[5]	宋奥微, 王文文, 田芬芳, 邢莉莉, 牛佳萌, 常婧妍, 杨颖群, 马婷, 王文华, 杨江存, 孙杨. 中国人群红细胞意外抗体阳性率调查及特异性抗体分布特征^*[J]. 临床输血与检验, 2025, 27(3): 291-299.
[6]	付晓艳, 甄自达, 马曙轩. Ⅳ期高危神经母细胞瘤患儿自体造血干细胞移植红细胞输注的影响因素分析[J]. 临床输血与检验, 2025, 27(3): 300-305.
[7]	孙莉萍, 曹腾宇, 段翠密, 于洋. 利用细胞化学染色方法和原位杂交技术探讨红细胞中核酸物质表达及定位情况^*[J]. 临床输血与检验, 2025, 27(3): 325-328.
[8]	李济洋, 李辰琰, 周欠欠, 詹林盛. 一种红细胞同种异体免疫动物模型的构建^*[J]. 临床输血与检验, 2025, 27(3): 340-346.
[9]	赵薇, 郑子薇, 卢发强, 杨宜承. 评估甘露醇-腺嘌呤-磷酸盐（MAP）溶液重悬洗涤红细胞的质量和储存期限^*[J]. 临床输血与检验, 2025, 27(3): 378-383.
[10]	张媛媛, 王慧茹, 应美爱, 潘健, 刘磊, 刘会兰. 血浆置换联合抗B细胞治疗药物应用于造血干细胞移植DSA阳性患者中的效果观察^*[J]. 临床输血与检验, 2025, 27(2): 156-162.
[11]	蔡茵, 陈至颖, 蒋苓, 任亚娜, 郑岚, 周国平. 上海地区无偿献血人群HLA抗体筛查分析[J]. 临床输血与检验, 2024, 26(6): 777-780.
[12]	齐畅, 孟祥红. 红细胞免疫相关表面抗原及其功能^*[J]. 临床输血与检验, 2024, 26(6): 855-858.
[13]	朱心怡, 张成鑫, 王秋实, 李佳佳, 齐永, 向东, 赵俸涌. 常见红细胞添加剂成分对双花扁豆凝集素与A₁红细胞反应的影响^*[J]. 临床输血与检验, 2024, 26(5): 587-591.
[14]	蒋雪玉, 杨懿铭, 孙娟, 谢如锋, 高跞, 杨洁. 黄芩苷预治疗对小鼠红细胞输注模型中IgG和IgM抑制作用的研究^*[J]. 临床输血与检验, 2024, 26(5): 604-608.
[15]	苏晓敏, 张国权, 王锦, 徐华. 基于蛋白组学和代谢组学在血液存储中相关性分析[J]. 临床输血与检验, 2024, 26(5): 609-616.